Yu-Ih Hou – Mayor, New Taipei City, Taiwan
Yu-Ih Hou, mayor of New Taipei City, introduces the city and highlights its key competitive advantages and strategic direction of growth as Taiwan’s top economic and cultural destination. Over…
CHUGAI PHARMACEUTICAL CO., LTD- founded in 1925- is committed to providing high-quality healthcare and improving people’s health, well-being and quality of life. With global horizon, Chugai is increasingly focusing on Research and Development (R&D). Our mission today and tomorrow is to create exceptional added value in healthcare, and proceed to be a leading international health care company.
To service Taiwan, Chugai set up a Taipei branch company in 1988, and merged with HUEY MAW TRADING CO., LTD. to become CHUNG HUEY PHARMACEUTICAL CO., LTD. in 1991. In October 2001, the company officially changed the name to CHUGAI PHARMA TAIWAN and reran the business for marketing hospital-based products. Most of the pharmaceutical products import from Japan headquarters directly and part of them are toll manufacture locally; furthermore, CHUGAI PHARMA TAIWAN CO., LTD and SHUN HWA CO., LTD are responsible for marketing business to remain constant: to improving patient care.
Major products
GRANOCYTE (Recombinant Human Granocyte Colony-Stimulating Factor Preparation)
SIGMART (Anti Angina Pectoris Agent)
Company Name: Chugai Pharma Taiwan Ltd.
Address: 3Fl., No. 73, ZhouZi Street, Neihu District,Taipei 10493, Taiwan
Telephone: (02)2658-8800
Fax: (02)2658-8852
E-Mail: cpt@chugai.com.tw
Website: www.chugai-pharm.co.jp
Yu-Ih Hou, mayor of New Taipei City, introduces the city and highlights its key competitive advantages and strategic direction of growth as Taiwan’s top economic and cultural destination. Over…
Wei-Hong Tseng, founder and chairman of PharmaCore Biotech, introduces the specialized CDMO and its unique capacities to produce high value-added products. As a leading service provider in Taiwan, Tseng goes…
Carol Cheng, chief operating officer of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), gives an update on the current condition of Taiwan’s biopharma environment and speaks about the country’s innovative…
Bach Chen, CEO of Maisense, highlights the innovative new solutions that the company has created in cardiovascular preventative medicine. Their advanced technology, Freescan, is providing an advanced solution to prevent…
Alan Tsai, general manager, and Carson Chen, chief technology officer of iXensor introduce the startup as an innovative player in the point-of-care diagnostics and digital health space. They jointly discuss…
Dr Jan-Mou Lee, founder of FullHope Biomedical, shares his story of how he came to establish his company after a realization about the loss of impact that occurs when critical…
Arthur Kadurin, CEO of Insilico Medicine Taiwan, tells us how artificial intelligence can change drug discovery process using the innovative generative adversarial networks (GANs) approach. AI is the future…
Ed Deng, co-founder and CEO of Health2Sync, a digital health startup specialized in diabetes management, shares how the application is revolutionizing the ability of patients to take control of the…
Tsung-Tsong Wu, minister without portfolio, offers insights into the current state of Taiwan’s biomedical landscape three years after the administration’s Biomedical Industry Innovation Program was put into place to bolster…
Dr Tse Wen Chang, founder of Immunwork, gives an update on the preclinical development process of the company’s revolutionary T-E pharmaceutical products and goes on to give his expert insights…
Dr James Chih-Hsin Yang, director of National Taiwan University Hospital’s department of oncology, speaks about oncology in Taiwan and the role that the NTU network plays in the island’s oncology…
Rongjin Lin, chairman of Center Ventures and Center Laboratories shares his story of how he revived Center Laboratories from the brink of bankruptcy and repositioned the pharmaceutical company to become…
See our Cookie Privacy Policy Here